Literature DB >> 35334447

Structure-activity relationship studies on O-alkylamino-tethered salicylamide derivatives with various amino acid linkers as potent anticancer agents.

Jimin Xu1, Hyejin Kim2, Jiabin Dong2, Haiying Chen1, Junhai Xu2, Ruixia Ma2, Mingxiang Zhou1, Tianzhi Wang3, Qiang Shen4, Jia Zhou5.   

Abstract

In our continued SAR study efforts, a series of O-alkylamino-tethered salicylamide derivatives with various amino acid linkers has been designed, synthesized, and biologically evaluated as potent anticancer agents. Five selected compounds with different representative chemical structures were found to show broad anti-proliferative activities, effective against all tested ER-positive breast cancer (BC) and triple-negative breast cancer (TNBC) cell lines with low micromolar IC50 values. Among these compounds, compound 9a (JMX0293) maintained good potency against MDA-MB-231 cell line (IC50 = 3.38 ± 0.37 μM) while exhibiting very low toxicity against human non-tumorigenic breast epithelial cell line MCF-10A (IC50 > 60 μM). Further mechanistic studies showed that compound 9a could inhibit STAT3 phosphorylation and contribute to apoptosis in TNBC MDA-MB-231 cells. More importantly, compound 9a significantly suppressed MDA-MB-231 xenograft tumor growth in vivo without significant toxicity, indicating its great potential as a promising anticancer drug candidate for further clinical development.
Copyright © 2022 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anticancer agents; Breast cancer; Drug discovery; JMX0293; Niclosamide derivatives; STAT3 inhibitors

Mesh:

Substances:

Year:  2022        PMID: 35334447      PMCID: PMC9040195          DOI: 10.1016/j.ejmech.2022.114229

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   7.088


  40 in total

Review 1.  JAK-STAT signaling: from interferons to cytokines.

Authors:  Christian Schindler; David E Levy; Thomas Decker
Journal:  J Biol Chem       Date:  2007-05-14       Impact factor: 5.157

Review 2.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer.

Authors:  Daniel E Johnson; Rachel A O'Keefe; Jennifer R Grandis
Journal:  Nat Rev Clin Oncol       Date:  2018-02-06       Impact factor: 66.675

3.  Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts.

Authors:  Xiaolei Zhang; Peibin Yue; Brent D G Page; Tianshu Li; Wei Zhao; Andrew T Namanja; David Paladino; Jihe Zhao; Yuan Chen; Patrick T Gunning; James Turkson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-23       Impact factor: 11.205

Review 4.  STAT3 signaling: anticancer strategies and challenges.

Authors:  Paul A Johnston; Jennifer R Grandis
Journal:  Mol Interv       Date:  2011-02

5.  Discovery of N-substituted sulfamoylbenzamide derivatives as novel inhibitors of STAT3 signaling pathway based on Niclosamide.

Authors:  Xuebao Wang; Kaiqi Wu; Longcheng Fang; Xiaojiao Yang; Nan Zheng; Zongxuan Du; Ying Lu; Zixin Xie; Zhiguo Liu; Zhigui Zuo; Faqing Ye
Journal:  Eur J Med Chem       Date:  2021-03-17       Impact factor: 6.514

6.  Central role of the threonine residue within the p+1 loop of receptor tyrosine kinase in STAT3 constitutive phosphorylation in metastatic cancer cells.

Authors:  Zheng-Long Yuan; Ying-Jie Guan; Lijuan Wang; Wenyi Wei; Agnes B Kane; Y Eugene Chin
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

7.  Structure-Activity Relationship Studies on Diversified Salicylamide Derivatives as Potent Inhibitors of Human Adenovirus Infection.

Authors:  Jimin Xu; Judith Berastegui-Cabrera; Haiying Chen; Jerónimo Pachón; Jia Zhou; Javier Sánchez-Céspedes
Journal:  J Med Chem       Date:  2020-02-28       Impact factor: 7.446

Review 8.  Niclosamide: Beyond an antihelminthic drug.

Authors:  Wei Chen; Robert A Mook; Richard T Premont; Jiangbo Wang
Journal:  Cell Signal       Date:  2017-04-04       Impact factor: 4.315

9.  HJC0152, a novel STAT3 inhibitor with promising anti-tumor effect in gastric cancer.

Authors:  Xiaoxia Jiang; Mengjie Wu; Zhenzhen Xu; Haohao Wang; Haiyong Wang; Xiongfei Yu; Zhongqi Li; Lisong Teng
Journal:  Cancer Manag Res       Date:  2018-12-12       Impact factor: 3.989

Review 10.  Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.

Authors:  Jimin Xu; Pei-Yong Shi; Hongmin Li; Jia Zhou
Journal:  ACS Infect Dis       Date:  2020-03-10       Impact factor: 5.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.